ada.enesco, Author at European Medical Journal - Page 20 of 27

Real-Time Allergy Mapping with Internet-Based Surveillance

Seasonal allergies, which affect around 26% of Americans, come with significant economic and productivity costs, especially as climate change drives higher pollen and mould levels.

Novel Procedure May Eliminate Insulin Dependency in Type 2 Diabetes - UEG Week 2024

Pioneering research presented at UEG Week 2024 has revealed a new treatment approach for Type 2 diabetes that could reduce the need for insulin therapy.

New Imaging Technique Shows Promise for Personalised Oesophageal Cancer Treatment – UEG Week 2024

A study presented at UEGW 2024 is exploring a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced oesophageal cancer.

Study Identifies Pre-diagnostic Antibody Signatures in IBD – UEG Week 2024

A groundbreaking study presented at UEG Week 2024 has revealed distinct antibody responses in Crohn’s disease and ulcerative colitis apparent years before diagnosis.

Austrian Experts Call for Nationwide Colorectal Cancer Screening - UEG Week 2024

Leading health experts at UEG Week 2024 are calling for the implementation of a national, quality-assured colorectal cancer screening programme for individuals aged 45–75.

FLOW Trial Shows Benefit of Semaglutide in Type 2 Diabetes and CKD: EASD 2024

Findings from the FLOW trial, the first dedicated kidney outcomes trial with semaglutide in patients with Type 2 diabetes and chronic kidney disease, were presented at EASD 2024.

Predictors for Weight Loss and Glucose Control with Tirzepatide: EASD 2024

New analysis from the SURPASS-4 trial identifies crucial factors for maintaining blood glucose control and weight loss with tirzepatide in patients with Type 2 diabetes.

Early Control of Gestational Diabetes Reduces Childhood Obesity Risk: EASD 2024

A key study presented at EASD 2024 highlights that rapidly managing blood sugar in pregnant women with gestational diabetes reduces the risk of obesity in their children.

Time-Restricted Eating Improves Glycaemic Control in Adults at Risk of Type 2 Diabetes: EASD 2024

Time-restricted eating, limiting food intake to an 8-hour window, significantly improves blood sugar control in adults at risk of Type 2 diabetes, research from EASD 2024 shows.

Liraglutide Effective for Children with Obesity Aged Under 12 Years: EASD 2024

The SCALE Kids trial has found that weight-loss drug liraglutide is safe and effective for children aged 6 to under 12 years living with obesity.